Headache Education by E-Learning Through Social Networking Services (Social Media)

References

• Leonardi M. Burden of migraine: what should we say more? Neurol Sci. 2015;36(Suppl S1):1–3. doi:10.1007/s10072-015-2188-z
   PubMedGoogle Scholar
• Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23(1):34. doi:10.1186/s10194-022-01402-2
   PubMed Web of Science ®Google Scholar
• Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222. doi:10.1016/S0140-6736(20)30925-9
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Komori M, Tanji Y, Ozeki A, Hirata K. Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a Phase 2 randomized placebo-controlled trial. Expert Opin Drug Saf. 2022. doi:10.1080/14740338.2022.2078302
   Web of Science ®Google Scholar
• Suzuki K, Takeshima T, Igarashi H, et al. Impact of the COVID-19 pandemic on migraine in Japan: a multicentre cross-sectional study. J Headache Pain. 2021;22(1):53. doi:10.1186/s10194-021-01263-1
   PubMed Web of Science ®Google Scholar
• Takeshima T, Sakai F, Hirata K, et al. Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study. Headache. 2021;61(6):927–935. doi:10.1111/head.14138
   PubMed Web of Science ®Google Scholar
• Hirata K, Sakai F, Takeshima T, et al. Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial. J Headache Pain. 2021;22(1):110. doi:10.1186/s10194-021-01313-8
   PubMed Web of Science ®Google Scholar
• Hirata K, Ueda K, Komori M, et al. Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Curr Med Res Opin. 2021;37(11):1945–1955. doi:10.1080/03007995.2021.1971179
   PubMed Web of Science ®Google Scholar
• Matsumori Y, Ueda K, Komori M, et al. Burden of Migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study. Neurol Ther. 2022;11(1):205–222. doi:10.1007/s40120-021-00305-9
   PubMed Web of Science ®Google Scholar
• Suzuki N, Ishikawa Y, Gomi S, et al. Prevalence and characteristics of headaches in a socially active population working in the Tokyo metropolitan area -surveillance by an industrial health consortium. Internal Med. 2014;53(7):683–689. doi:10.2169/internalmedicine.53.1700
   PubMed Web of Science ®Google Scholar
• Shibata Y. [Clinical analysis of the patients with tension-type headache in whom kakkontou is effective] (Japanese). J Neurosurgery Kampo Med. 2019;5:16–18.
   Google Scholar
• Fujimoto T, Sato T, Sato R, Ohtaki K, Asai J, Hokata H. [Treatment of tension-type headache with kakkon-to associated with guidance of a way of life] (Japanese). Pain kampo med. 2001;11:9–13.
   Google Scholar
• Imai N, Yagi N, Kuroda R, Konishi T, Serizawa M, Kobari M. Clinical profile of cluster headaches in Japan: low prevalence of chronic cluster headache, and uncoupling of sense and behaviour of restlessness. Cephalalgia. 2011;31(5):628–633. doi:10.1177/0333102410391486
   PubMed Web of Science ®Google Scholar
• Imai N. [New management of cluster headache] (Japanese). Brain Nerve. 2021;73(4):347–355. doi:10.11477/mf.1416201766
   PubMedGoogle Scholar
• Imai N. A cluster headache responsive to ramelteon, a selective melatonin MT1/MT2 receptor agonist. Intern Med. 2016;55(17):2483–2485. doi:10.2169/internalmedicine.55.6621
   PubMed Web of Science ®Google Scholar
• Imai N, Kitamura E. Differences in clinical features of cluster headache between drinkers and nondrinkers in Japan. PLoS One. 2019;14(11):e0224407. doi:10.1371/journal.pone.0224407
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders. Cephalalgia. 2018;38(1):1–211. doi:10.1177/0333102417738202
   PubMed Web of Science ®Google Scholar
• Katsuki M, Kawahara J, Matsumori Y, et al. Questionnaire-based survey during COVID-19 vaccination on the prevalence of elderly’s migraine, chronic daily headache, and medication-overuse headache in one Japanese city—Itoigawa Hisui Study. J Clin Med. 2022;11(16):4707. doi:10.3390/jcm11164707
   PubMed Web of Science ®Google Scholar
• Katsuki M, Matsumori Y, Kawahara J, et al. School-based online survey on chronic headache, migraine, and medication-overuse headache prevalence among children and adolescents in Japanese one city - Itoigawa Benizuwaigani study. Clin Neurol Neurosurg. 2023;226:107610. doi:10.1016/j.clineuro.2023.107610
   PubMed Web of Science ®Google Scholar
• Katsuki M, Yamagishi C, Matsumori Y, et al. Questionnaire-based survey on the prevalence of medication-overuse headache in Japanese one city-Itoigawa study. Neurol Sci. 2022;43:3811–3822. doi:10.1007/s10072-021-05831-w
   PubMed Web of Science ®Google Scholar
• Takeshima T, Ishizaki K, Fukuhara Y, et al. Population-based door-to-door survey of migraine in Japan: the Daisen Study. J Head Face Pain. 2004;44(1):8–19. doi:10.1111/j.1526-4610.2004.04004.x
   PubMed Web of Science ®Google Scholar
• Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17(1):15–22. doi:10.1046/j.1468-2982.1997.1701015.x
   PubMed Web of Science ®Google Scholar
• Goto M, Yokoyama K, Nozaki Y, et al. Characteristics of headaches in Japanese elementary and junior high school students: a school-based questionnaire survey. Brain Dev. 2017;39(9):791–798. doi:10.1016/j.braindev.2017.05.010
   PubMed Web of Science ®Google Scholar
• Shimizu T, Sakai F, Miyake H, et al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021;22(1):29. doi:10.1186/s10194-021-01243-5
   PubMed Web of Science ®Google Scholar
• Nadaoka T, Kanda H, Oiji A, Morioka Y, Kashiwakura M, Totsuka S. Headache and stress in a group of nurses and government administrators in Japan. Headache. 1997;37(6):386–391. doi:10.1046/j.1526-4610.1997.3706386.x
   PubMed Web of Science ®Google Scholar
• Katsuki M, Matsumori Y, Kawahara J, et al. Headache education by leaflet distribution during COVID‐19 vaccination and school‐based on‐demand e‐learning: itoigawa Geopark Headache Awareness Campaign. J Head Face Pain. 2023;63(3):429–440. doi:10.1111/head.14472
   PubMed Web of Science ®Google Scholar
• Takeshima T, Wan Q, Zhang Y, et al. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain. 2019;20(1):111. doi:10.1186/s10194-019-1062-4
   PubMed Web of Science ®Google Scholar
• Sakai F, Igarashi H, Yokoyama M, et al. Diagnosis, knowledge, perception, and productivity impact of headache education and clinical evaluation program in the workplace at an information technology company of more than 70,000 employees. Cephalalgia. 2023;43(4):3331024231165682. doi:10.1177/03331024231165682
   Web of Science ®Google Scholar
• Ambat FDF, Bentivegna E, Martelletti P. Novel migraine therapies may reduce public and personal disadvantages for people with migraine. BioDrugs. 2022;36(3):337–339. doi:10.1007/s40259-022-00532-y
   PubMed Web of Science ®Google Scholar
• Serra López-Matencio JM, Gago-Veiga AB, Gómez M, et al. Treatment of migraine with monoclonal antibodies. Expert Opin Biol Ther. 2022;22(6):707–716. doi:10.1080/14712598.2022.2072207
   PubMed Web of Science ®Google Scholar
• Sakai F, Suzuki N, Kim BK, et al. Efficacy and safety of fremanezumab for episodic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61(7):1102–1111. doi:10.1111/head.14178
   PubMed Web of Science ®Google Scholar
• Sakai F, Takeshima T, Homma G, Tanji Y, Katagiri H, Komori M. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache. 2021;61(5):755–765. doi:10.1111/head.14122
   PubMed Web of Science ®Google Scholar
• Scheffler A, Schenk H, Wurthmann S, et al. CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience. J Headache Pain. 2021;22(1):111. doi:10.1186/s10194-021-01323-6
   PubMed Web of Science ®Google Scholar
• Ruscheweyh R, Broessner G, Goßrau G, et al. Effect of calcitonin gene-related peptide (-receptor) antibodies in chronic cluster headache: results from a retrospective case series support individual treatment attempts. Cephalalgia. 2020;40(14):1574–1584. doi:10.1177/0333102420949866
   PubMed Web of Science ®Google Scholar
• Takeshima T, Ueda K, Komori M, et al. Potential unmet needs in acute treatment of migraine in Japan: results of the OVERCOME (Japan) study. Adv Ther. 2022;39(11):5176–5190. doi:10.1007/s12325-022-02289-w
   PubMed Web of Science ®Google Scholar
• Headache Clinical Practice Guideline Development Committee C. 2021. [Clinical Practice Guideline for Headache Disorders 2021] (Japanese). Japanese Society of Neurology J, Japanese Headache Society J, Japanese Society of Neurological Therapeutics J, eds) Igaku-Shoin.
   Google Scholar
• Ozeki K, Noda T, Nakamura M, Ojima T. Weather and headache onset: a large-scale study of headache medicine purchases. Int J Biometeorol. 2015;59(4):447–451. doi:10.1007/s00484-014-0859-8
   PubMed Web of Science ®Google Scholar
• Carlsen LN, Westergaard ML, Bisgaard M, Schytz JB, Jensen RH. National awareness campaign to prevent medication-overuse headache in Denmark. Cephalalgia. 2018;38(7):1316–1325. doi:10.1177/0333102417736898
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Lipton RB, Dodick DW. Operational diagnostic criteria for chronic migraine: expert opinion. Headache. 2012;54(7):1258–1266. doi:10.1111/head.12407
   Web of Science ®Google Scholar
• Togha M, Karimitafti MJ, Ghorbani Z, et al. Characteristics and comorbidities of headache in patients over 50 years of age: a cross-sectional study. BMC Geriatr. 2022;22(1):1–10. doi:10.1186/s12877-022-03027-1
   PubMed Web of Science ®Google Scholar
• Huang L, Bourke D, Ranta A. The impact of an online adult headache guideline on headache referrals to the neurology clinic. Intern Med J. 2021;51(8):1251–1254. doi:10.1111/imj.14959
   PubMed Web of Science ®Google Scholar
• Ito Y, Mitsufuji T, Asano Y, et al. Naratriptan in the prophylactic treatment of cluster headache. Intern Med. 2017;56(19):2579–2582. doi:10.2169/internalmedicine.8865-17
   PubMed Web of Science ®Google Scholar
• Odaguchi H, Wakasugi A, Ito H, et al. The efficacy of goshuyuto, a typical Kampo (Japanese herbal medicine) formula, in preventing episodes of headache. Curr Med Res Opin. 2006;22(8):1587–1597. doi:10.1185/030079906X112769
   PubMed Web of Science ®Google Scholar
• Mitsufuji T, Yamamoto T, Miyake A, et al. [Use of yokukansan for the treatment of headaches caused by medication overuse, second report: effectiveness of administering only yokukansan] (Japanese). J Japanese Assoc Oriental Psychosomatic Medicine. 2014;29(1):84–87.
   Google Scholar
• Mitsufuji T, Yamamoto T, Hayashi Y, Mizoi Y, Tamura N, Araki N. [Use of yokukansan for the treatment of medication overuse headache] (Japanese). J Japanese Assoc Oriental Psychosomatic Medicine. 2013;28(1):47–49.
   Google Scholar
• Sakai F. Beat the stigma of primary headache disorders: activities of JPAC and GPAC. Neurol Clin Neurosci. 2020;8(3):128–131. doi:10.1111/ncn3.12374
   Web of Science ®Google Scholar
• Ohyama S, Yokota C, Miyashita F, et al. Effective education materials to advance stroke awareness without teacher participation in junior high school students. J Stroke Cerebrovasc Dis. 2015;24(11):2533–2538. doi:10.1016/j.jstrokecerebrovasdis.2015.07.001
   PubMed Web of Science ®Google Scholar
• Hino T, Yokota C, Nishimura K, et al. Spreading awareness of stroke through school-based education: a pooled analysis of three community-based studies. J Stroke Cerebrovasc Dis. 2018;27(7):1810–1814. doi:10.1016/j.jstrokecerebrovasdis.2018.02.008
   PubMed Web of Science ®Google Scholar
• Matsuzono K, Yokota C, Takekawa H, et al. Effects of stroke education of junior high school students on stroke knowledge of their parents: Tochigi project. Stroke. 2015;46(2):572–574. doi:10.1161/STROKEAHA.114.007907
   PubMed Web of Science ®Google Scholar
• Lebedeva ER, Olesen J, Osipova VV, Volkova LI, Tabeeva GR, Steiner TJ. The Yekaterinburg headache initiative: an interventional project, within the Global Campaign against Headache, to reduce the burden of headache in Russia. J Headache Pain. 2013;14:101. doi:10.1186/1129-2377-14-101
   PubMed Web of Science ®Google Scholar
• Lai JTF, Dereix JDC, Ganepola RP, et al. Should we educate about the risks of medication overuse headache? J Headache Pain. 2014;15:10. doi:10.1186/1129-2377-15-10
   PubMed Web of Science ®Google Scholar
• Nagai K, Hayashi K, Yasui T, et al. Disease history and risk of comorbidity in women’s life course: a comprehensive analysis of the Japan Nurses’ Health Study baseline survey. BMJ Open. 2015;5(3):e006360. doi:10.1136/bmjopen-2014-006360
   PubMed Web of Science ®Google Scholar
• Chen SJ, Chen CH, Chang HY. Effects of inhaling essential oil on headache-related quality of life among nurses working in emergency and critical care units. Hu Li Za Zhi. 2021;68(5):51–64. doi:10.6224/JN.202110_68(5).08
   PubMedGoogle Scholar
• Diao T, Zhu J, Yu L, Ma X. Correlation analysis of vestibular symptoms and migraine and non-migraine headaches: an epidemiological survey of 708 female nurses. Front Neurosci. 2022;16:925095. doi:10.3389/fnins.2022.925095
   PubMed Web of Science ®Google Scholar
• Durham CF, Alden KR, Dalton JA, et al. Quality of life and productivity in nurses reporting migraine. Headache. 1998;38(6):427–435. doi:10.1046/j.1526-4610.1998.3806427.x
   PubMed Web of Science ®Google Scholar
• Menon B, Remadevi N. Migraine in nursing students-A study from a tertiary care center in South India. J Neurosci Rural Pract. 2021;12(1):129–132. doi:10.1055/s-0040-1721556
   PubMedGoogle Scholar
• Viticchi G, Falsetti L, Pettinari P, Provinciali L, Silvestrini M, Bartolini M. Headache in a population of hospital workers. Neurol Sci. 2014;35(Suppl 1):157–158. doi:10.1007/s10072-014-1759-8
   PubMedGoogle Scholar
• Bartolini M, Viticchi G, Falsetti L, et al. Migraine in health workers: working in a hospital can be considered an advantage? Neurol Sci. 2014;35(Suppl 1):27–29. doi:10.1007/s10072-014-1737-1
   PubMedGoogle Scholar
• Wang Y, Xie J, Yang F, et al. The prevalence of primary headache disorders and their associated factors among nursing staff in North China. J Headache Pain. 2015;16:4. doi:10.1186/1129-2377-16-4
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Kawai H, Nishiwaki K, et al. [The outbreak situation of the physical symptom in the musical instrument exercise of the high school brass band club student] (Japanese). Ann Rep Faculty Rehabilitation Shijonawate Gakuen Univ. 2010;6:13–18.
   Google Scholar
• Santos IS, Griep RH, Alves MGM, et al. Job stress is associated with migraine in current workers: the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Eur J Pain. 2014;18(9):1290–1297. doi:10.1002/j.1532-2149.2014.489.x
   PubMed Web of Science ®Google Scholar
• Sandoe CH, Sasikumar S, Lay C, Lawler V. The impact of shift work on migraine: a case series and narrative review. Headache. 2019;59(9):1631–1640. doi:10.1111/head.13622
   PubMed Web of Science ®Google Scholar
• Roberts DL, Vargas BB. The portrayal of migraine in popular music: observations and implications. Headache. 2012;52(7):1164–1170. doi:10.1111/j.1526-4610.2012.02159.x
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Tatsumoto M, Maki K, Mitsui M, Hasegawa H, Hirata K. Identification of everyday sounds perceived as noise by migraine patients. Intern Med. 2019;58(11):1565–1572. doi:10.2169/internalmedicine.2206-18
   PubMed Web of Science ®Google Scholar
• Hassler M, Gupta D. Functional brain organization, handedness, and immune vulnerability in musicians and non-musicians. Neuropsychologia. 1993;31(7):655–660. doi:10.1016/0028-3932(93)90137-o
   PubMed Web of Science ®Google Scholar
• Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43–46.
   PubMedGoogle Scholar
• Steiner TJ, Birbeck GL, Jensen RH, et al. The Global Campaign turns 18: a brief review of its activities and achievements. J Headache Pain. 2022;23(1):49. doi:10.1186/s10194-022-01420-0
   PubMed Web of Science ®Google Scholar
• Togha M, Rafiee P, Ghorbani Z, et al. The prevalence of headache disorders in children and adolescents in Iran: a schools-based study. Cephalalgia. 2022;42(11–12):1246–1254. doi:10.1177/03331024221103814
   PubMed Web of Science ®Google Scholar
• Kawatu N, Wa Somwe S, Ciccone O, et al. The prevalence of primary headache disorders in children and adolescents in Zambia: a schools-based study. J Headache Pain. 2022;23(1):118. doi:10.1186/s10194-022-01477-x
   PubMed Web of Science ®Google Scholar
• Luvsannorov O, Anisbayar T, Davaasuren M, et al. The prevalence of headache disorders in children and adolescents in Mongolia: a nationwide schools-based study. J Headache Pain. 2020;21(1):107. doi:10.1186/s10194-020-01175-6
   PubMed Web of Science ®Google Scholar
• Genc D, Vaičienė-Magistris N, Zaborskis A, et al. The prevalence of headache disorders in children and adolescents in Lithuania: a schools-based study. J Headache Pain. 2020;21(1):73. doi:10.1186/s10194-020-01146-x
   PubMed Web of Science ®Google Scholar
• Kohda T, Nagata H. 「複合メディア環境」におけるテレビ視聴者行動 [Survey on television viewers’ behavior under ‘complex media-environment’]. J Information Media Studies. 2012;11:15–31. Japanese. doi:10.11304/jims.11.15
   Google Scholar
• Ministry of Internal Affairs and Communications M. Available from: [The Evolving Digital Economy and Beyond Society 5.0]. Japanese; 2019. https://www.soumu.go.jp/johotsusintokei/whitepaper/ja/r01/html/nd114120.html. Accessed October 25, 2023.
   Google Scholar
• Rattanawong W, Rapoport A, Srikiatkhachorn A. Neurobiology of migraine progression. Neurobiol Pain. 2022;12:100094. doi:10.1016/j.ynpai.2022.100094
   PubMedGoogle Scholar
• Natoli J, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599–609. doi:10.1111/j.1468-2982.2009.01941.x
   PubMed Web of Science ®Google Scholar
• Ishii R, Schwedt TJ, Dumkrieger G, et al. Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache. 2021;61(7):992–1003. doi:10.1111/head.14154
   PubMed Web of Science ®Google Scholar
• Torres-Ferrús M, Quintana M, Fernandez-Morales J, Alvarez-Sabin J, Pozo-Rosich P. When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. Cephalalgia. 2017;37(2):104–113. doi:10.1177/0333102416636055
   PubMed Web of Science ®Google Scholar
• Schulte LH, Allers A, May A. Hypothalamus as a mediator of chronic migraine: evidence from high-resolution fMRI. Neurology. 2017;88(21):2011–2016. doi:10.1212/WNL.0000000000003963
   PubMed Web of Science ®Google Scholar
• Aurora SK, Barrodale PM, Tipton RL, Khodavirdi A. Brainstem dysfunction in chronic migraine as evidenced by neurophysiological and positron emission tomography studies. Headache. 2007;47(7):996–1003. doi:10.1111/j.1526-4610.2007.00853.x.
   PubMed Web of Science ®Google Scholar
• Förderreuther S, Zhang Q, Stauffer VL, Aurora SK, Láinez MJA. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain. 2018;19(1):121. doi:10.1186/s10194-018-0951-2
   PubMed Web of Science ®Google Scholar
• Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;21(1):61. doi:10.1186/s10194-020-01127-0
   PubMed Web of Science ®Google Scholar
• McAllister P, Cohen JM, Campos VR, Ning X, Janka L, Barash S. Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies. J Headache Pain. 2022;23(1):112. doi:10.1186/s10194-022-01438-4
   PubMed Web of Science ®Google Scholar
• Barbanti P, Egeo G, Aurilia C, et al. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain. 2022;23(1):46. doi:10.1186/s10194-022-01396-x
   PubMed Web of Science ®Google Scholar
• Nahas SJ, Naegel S, Cohen JM, et al. Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies. J Headache Pain. 2021;22(1):141. doi:10.1186/s10194-021-01351-2
   PubMed Web of Science ®Google Scholar
• Hirata K, Sano H, Kondo H, Shibasaki Y, Koga N. Clinical characteristics, medication use, and impact of primary headache on daily activities: an observational study using linked online survey and medical claims data in Japan. BMC Neurol. 2023;23(1):80. doi:10.1186/s12883-023-03122-9
   PubMed Web of Science ®Google Scholar
• Igarashi H, Shibata M, Ozeki A, Day KA, Matsumura T. Early onset and maintenance effect of galcanezumab in Japanese patients with episodic migraine. J Pain Res. 2021;14:3555–3564. doi:10.2147/JPR.S326905
   PubMed Web of Science ®Google Scholar
• Katsuki M, Kashiwagi K, Kawamura S, Tachikawa S, Koh A. One-time use of galcanezumab or fremanezumab for migraine prevention. Cureus. 2023;15(1):e34180. doi:10.7759/cureus.34180
   PubMed Web of Science ®Google Scholar
• Tatsuoka Y, Takeshima T, Ozeki A, Matsumura T. Treatment satisfaction of galcanezumab in Japanese patients with episodic migraine: a phase 2 randomized controlled study. Neurol Ther. 2021;10(1):265–278. doi:10.1007/s40120-021-00236-5
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Stauffer VL, Day KA, Lipsius S, Wilson MC. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain. 2019;20(1):75. doi:10.1186/s10194-019-1024-x
   PubMed Web of Science ®Google Scholar
• Ito Y, Mitsufuji T, Okada M, et al. Early effect of calcitonin gene-related peptide monoclonal antibodies in migraine with medication overuse: a single-center retrospective study. Intern Med. 2023. doi:10.2169/internalmedicine.1471-22
   Web of Science ®Google Scholar
• Ihara K, Ohtani S, Watanabe N, et al. Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study. J Headache Pain. 2023;24(1):23. doi:10.1186/s10194-023-01556-7
   PubMed Web of Science ®Google Scholar
• Lau JTF, Yu A, Cheung JCK, Leung SSF. Studies on common illnesses and medical care utilization patterns of adolescents in Hong Kong. J Adolescent Health. 2000;27(6):443–452. doi:10.1016/S1054-139X(99)00075-0
   PubMed Web of Science ®Google Scholar
• Urtecho M, Wagner B, Wang Z, et al. A qualitative evidence synthesis of patient perspectives on migraine treatment features and outcomes. Headache. 2023;63(2):185–201. doi:10.1111/head.14430
   PubMed Web of Science ®Google Scholar
• Biagianti B, Grazzi L, Gambini O, et al. Decision-making deficit in chronic migraine patients with medication overuse. Neurol Sci. 2012;33(Suppl 1):S151–5. doi:10.1007/s10072-012-1071-4
   PubMedGoogle Scholar
• Kato Y, Poh W, Horvath Z, Cadiou F, Shimazu T, Maruki Y. Impact of COVID-19 pandemic on migraine management in the United States: insights from migraine tracking app users. BMC Neurol. 2021;21(1):345. doi:10.1186/s12883-021-02378-3
   PubMed Web of Science ®Google Scholar
• Katsuki M, Tatsumoto M, Kimoto K, et al. Investigating the effects of weather on headache occurrence using a smartphone application and artificial intelligence: a retrospective observational cross-sectional study. Headache. 2023.
   Web of Science ®Google Scholar
• Sasaki R, Yunoki T, Nakano Y, et al. Actual telemedicine needs of Japanese patients with neurological disorders in the COVID-19 pandemic. Intern Med. 2023;62(3):365–371. doi:10.2169/internalmedicine.9702-22
   PubMed Web of Science ®Google Scholar
• Katsuki M. The first case series from Japan of primary headache patients treated by completely online telemedicine. Cureus. 2022;14(11):e31068. doi:10.7759/cureus.31068
   PubMed Web of Science ®Google Scholar
• Parlongue G, Cerdan EV, Koenig J, Williams DP. Smartphone based music intervention in the treatment of episodic migraine headaches - A pilot trial. Complement Ther Med. 2021;63:102779. doi:10.1016/j.ctim.2021.102779
   PubMed Web of Science ®Google Scholar
• Jonker L, Fitzgerald L, Vanderpol J, Fisher S. Digital diary app use for migraine in primary care: prospective cohort study. Clin Neurol Neurosurg. 2022;216:107225. doi:10.1016/j.clineuro.2022.107225
   PubMed Web of Science ®Google Scholar
• Katsuki M, Narita N, Matsumori Y, et al. Preliminary development of a deep learning-based automated primary headache diagnosis model using Japanese natural language processing of medical questionnaire. Surg Neurol Int. 2020;11:475. doi:10.25259/SNI_827_2020
   PubMedGoogle Scholar
• Rosignoli C, Ornello R, Onofri A, et al. Applying a biopsychosocial model to migraine: rationale and clinical implications. J Headache Pain. 2022;23(1):100. doi:10.1186/s10194-022-01471-3
   PubMed Web of Science ®Google Scholar
• Adusumilli G, Kallmes KM, Kobeissi H, Kallmes DF, Heit JJ. Into the meta-verse: the decade of global knowledge sharing. Interv Neuroradiol. 2023;15910199231154704. doi:10.1177/15910199231154704
   Web of Science ®Google Scholar
• Berry PA. Migraine disorder: workplace implications and solutions. AAOHN J. 2007;55(2):51–56. doi:10.1177/216507990705500202
   PubMedGoogle Scholar
• Yamakawa M, Tachibana A, Tatsumoto M, Okajima K, Ueda S, Hirata K. Hemodynamic responses related to intrinsically photosensitive retinal ganglion cells in migraine. Neurosci Res. 2020;160:57–64. doi:10.1016/j.neures.2019.11.011
   PubMed Web of Science ®Google Scholar
• Dahal HN, Kharel Sitaula R. Visual impact of digital classroom among students attending online education. J Nepal Health Res Counc. 2022;20(2):405–411. doi:10.33314/jnhrc.v20i02.4041
   PubMedGoogle Scholar
• Tatsumoto M, Suzuki E, Nagata M, Suzuki K, Hirata K. Prophylactic treatment for patients with migraine using blue cut for night glass. Intern Med. 2022. doi:10.2169/internalmedicine.0132-22
   PubMedGoogle Scholar
• Horiguchi H, Suzuki E, Kubo H, et al. Efficient measurements for the dynamic range of human lightness perception. Jpn J Ophthalmol. 2021;65(3):432–438. doi:10.1007/s10384-020-00808-2
   PubMed Web of Science ®Google Scholar